{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:53:11Z","timestamp":1785552791822,"version":"3.56.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Antibody-drug conjugates (ADCs) have been implicated in myelosuppression and peripheral neuropathy (PN), possibly owing to their payload. Thus, their systemic toxicity should be considered. However, reports documenting adverse event (AE) occurrences in clinical settings are limited. This study analyzed AEs associated with polatuzumab vedotin, brentuximab vedotin, and enfortumab vedotin\u2014which share a common payload\u2014based on patient background factors using Japanese and United States AE spontaneous reporting databases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>This study examined data from the Japanese Adverse Drug Event Report database (April 2004-June 2023) and the Food and Drug Administration AE Reporting System (first quarter of 1997-third quarter of 2023). Safety signals for an AEs were defined as a reporting odds ratio lower limit of the 95% confidence interval &amp;gt;1. Additionally, AEs were stratified based on sex, age, and body mass index to explore correlations between patient demographics and AEs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Signals of PN, myelosuppression, and febrile neutropenia were detected in all ADCs. Polatuzumab vedotin showed earlier PN onset than other drugs and rare AEs such as heart failure. Enfortumab vedotin had widely detected skin-related AEs. Stratified analysis showed more AEs in males aged \u226560 years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our study identifies common AEs, including PN and myelosuppression in ADCs sharing the same payload. Onset duration and outcomes of each AE vary among ADCs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf298","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T12:53:59Z","timestamp":1758632039000},"source":"Crossref","is-referenced-by-count":7,"title":["Adverse events of antibody-drug conjugates: comparative analysis of agents with a common payload using the adverse event spontaneous reporting database"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5175-1413","authenticated-orcid":false,"given":"Kenta","family":"Yamaoka","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Kobe City Medical Center General Hospital , Kobe, Hyogo, 650-0047,","place":["Japan"]},{"name":"School of Pharmacy, Hyogo Medical University , Kobe, Hyogo, 650-8530,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Masago","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Hyogo Medical University , Kobe, Hyogo, 650-8530,","place":["Japan"]},{"name":"Department of Pharmacy, Shinko Hospital , Kobe, Hyogo, 651-0072,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayako","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kyushu University Hospital , Fukuoka, 812-8582,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Uesawa","sequence":"additional","affiliation":[{"name":"Department of Medical Molecular Informatics, Meiji Pharmaceutical University , Tokyo, 204-8588,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Muroi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kobe City Medical Center General Hospital , Kobe, Hyogo, 650-0047,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Shimizu","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Hyogo Medical University , Kobe, Hyogo, 650-8530,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"2025101312313962300_oyaf298-B1","doi-asserted-by":"publisher","first-page":"1951427","DOI":"10.1080\/19420862.2021.1951427","article-title":"Targeting cancer with antibody-drug conjugates: promises and challenges","volume":"13","author":"Dean","year":"2021","journal-title":"MAbs"},{"key":"2025101312313962300_oyaf298-B2","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.3390\/molecules25204764","article-title":"Antibody-drug conjugates for cancer therapy","volume":"25","author":"Hafeez","year":"2020","journal-title":"Molecules"},{"key":"2025101312313962300_oyaf298-B3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11912-015-0466-9","article-title":"Development and integration of antibody-drug conjugate in non-Hodgkin lymphoma","volume":"17","author":"Mehta","year":"2015","journal-title":"Curr Oncol Rep"},{"key":"2025101312313962300_oyaf298-B4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"2025101312313962300_oyaf298-B5","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/jnci\/djz035","article-title":"Antibody-drug conjugate-based therapeutics: state of the science","volume":"111","author":"Birrer","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"2025101312313962300_oyaf298-B6","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s40264-018-0775-7","article-title":"Safety and tolerability of antibody-drug conjugates in cancer","volume":"42","author":"Wolska-Washer","year":"2019","journal-title":"Drug Saf"},{"key":"2025101312313962300_oyaf298-B7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4161\/mabs.22854","article-title":"Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates","volume":"5","author":"Ritchie","year":"2013","journal-title":"MAbs"},{"key":"2025101312313962300_oyaf298-B8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1146\/annurev-med-061516-121357","article-title":"Antibody-drug conjugates for cancer treatment","volume":"69","author":"Lambert","year":"2018","journal-title":"Annu Rev Med"},{"key":"2025101312313962300_oyaf298-B9","doi-asserted-by":"publisher","first-page":"6389","DOI":"10.1158\/1078-0432.CCR-11-1417","article-title":"Antibody conjugate therapeutics: challenges and potential","volume":"17","author":"Teicher","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2025101312313962300_oyaf298-B10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2018","journal-title":"Protein Cell"},{"key":"2025101312313962300_oyaf298-B11","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","article-title":"Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates","volume":"8","author":"Donaghy","year":"2016","journal-title":"MAbs"},{"key":"2025101312313962300_oyaf298-B12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"2025101312313962300_oyaf298-B13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4161\/mabs.27022","article-title":"Site-specific antibody drug conjugates for cancer therapy","volume":"6","author":"Panowski","year":"2014","journal-title":"MAbs"},{"key":"2025101312313962300_oyaf298-B14","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.apsb.2020.04.012","article-title":"Recent advances of antibody drug conjugates for clinical applications","volume":"10","author":"Zhao","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"2025101312313962300_oyaf298-B15","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"key":"2025101312313962300_oyaf298-B16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025101312313962300_oyaf298-B17","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"key":"2025101312313962300_oyaf298-B18","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"2025101312313962300_oyaf298-B19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/2040620712443076","article-title":"Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma","volume":"3","author":"Vaklavas","year":"2012","journal-title":"Ther Adv Hematol"},{"key":"2025101312313962300_oyaf298-B20","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"key":"2025101312313962300_oyaf298-B21","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"2025101312313962300_oyaf298-B22","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1159\/000529341","article-title":"Cardiac adverse events associated with multiple myeloma patients treated with proteasome inhibitors","volume":"101","author":"Fujiwara","year":"2023","journal-title":"Oncology"},{"key":"2025101312313962300_oyaf298-B23","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.3390\/life12091355","article-title":"Comprehensive analysis of adverse events induced by PARP inhibitors using JADER and time to onset","volume":"12","author":"Yamaoka","year":"2022","journal-title":"Life (Basel)"},{"key":"2025101312313962300_oyaf298-B24","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1159\/000531390","article-title":"Adverse event profile of azacitidine: analysis by route of administration using Japanese pharmacovigilance database","volume":"101","author":"Yamaoka","year":"2023","journal-title":"Oncology"},{"key":"2025101312313962300_oyaf298-B25","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/gb-2003-4-4-210","article-title":"Statistical tests for differential expression in cDNA microarray experiments","volume":"4","author":"Cui","year":"2003","journal-title":"Genome Biol"},{"key":"2025101312313962300_oyaf298-B26","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3390\/ph16040626","article-title":"Examination of risk factors and expression patterns of atypical femoral fractures using the Japanese adverse drug event report database: a retrospective pharmacovigilance study","volume":"16","author":"Toriumi","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"2025101312313962300_oyaf298-B27","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.3390\/ph16101500","article-title":"Comprehensive study of drug-induced pruritus based on adverse drug reaction report database","volume":"16","author":"Nakao","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"2025101312313962300_oyaf298-B28","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1182\/blood-2009-02-205500","article-title":"Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma","volume":"114","author":"Dornan","year":"2009","journal-title":"Blood"},{"key":"2025101312313962300_oyaf298-B29","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1158\/1535-7163.MCT-08-0388","article-title":"Anti-CD30 diabody-drug conjugates with potent antitumor activity","volume":"7","author":"Kim","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"2025101312313962300_oyaf298-B30","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","article-title":"Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","volume":"16","author":"Palanca-Wessels","year":"2015","journal-title":"Lancet Oncol"},{"key":"2025101312313962300_oyaf298-B31","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1007\/s10637-019-00844-x","article-title":"A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma","volume":"38","author":"Takahashi","year":"2020","journal-title":"Invest New Drugs"},{"key":"2025101312313962300_oyaf298-B32","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"key":"2025101312313962300_oyaf298-B33","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"key":"2025101312313962300_oyaf298-B34","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"key":"2025101312313962300_oyaf298-B35","doi-asserted-by":"publisher","first-page":"43205","DOI":"10.1074\/jbc.M103810200","article-title":"Nectin4\/PRR4, a new afadin-associated member of the nectin family that trans-interacts with nectin1\/PRR1 through V domain interaction","volume":"276","author":"Reymond","year":"2001","journal-title":"J Biol Chem"},{"key":"2025101312313962300_oyaf298-B36","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/jjco\/hyad170","article-title":"Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort","volume":"54","author":"Miyake","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"2025101312313962300_oyaf298-B37","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1002\/cam4.5165","article-title":"Japanese subgroup analysis of EV-301: an open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma","volume":"12","author":"Matsubara","year":"2023","journal-title":"Cancer Med"},{"key":"2025101312313962300_oyaf298-B38","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlich\u2019s magic bullet concept: 100 years of progress","volume":"8","author":"Strebhardt","year":"2008","journal-title":"Nat Rev Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf298\/64353845\/oyaf298.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/10\/oyaf298\/64353845\/oyaf298.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/10\/oyaf298\/64353845\/oyaf298.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T16:31:46Z","timestamp":1760373106000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf298\/8262301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf298","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,9,23]]},"article-number":"oyaf298"}}